| HOME >> BIOLOGY >> TECHNOLOGY |
Months Protection Equity Endovas- Months
Ended Disconti- Accelera- cular Ended
June 30, nuance tion Business June 30,
2008 2008 2008 2008 2008
Revenues:
Net sales
Biomate-
rials $13,330,890 $- $- $- $13,330,890
Endovas-
cular 1,637,713 - - - 1,637,713
Total net
sales 14,968,603 - - - 14,968,603
Research
and
development - - - - -
Royalty
income 7,003,252 - - - 7,003,252
Total
revenues 21,971,855 - - - 21,971,855
Operating costs
and expenses:
Cost of
products
sold 9,097,198 - - (2,012,734) 7,084,464
Research
and
development 4,339,583 - - (10,250) 4,329,333
Sales and
marketing 4,232,527 - - (2,382,915) 1,849,612
General and
admini-
strative 4,851,947 - - (2,482,929) 2,369,018
Loss on
sale of
endovascular
assets 1,212,478 (1,212,478) -
Total
operating
costs and
expenses 23,733,733 - - (8,101,306) 15,632,427
(Loss) Income
from
operations (1,761,878) - - 8,101,306 6,339,428
Interest and
other income,
net (263,568) - - - (263,568)
Pre-tax (loss)
income (2,025
'/>"/>
| SOURCE Kensey Nash Corporation Copyright©2008 PR Newswire. All rights reserved |